Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Asset disposition
Inv. presentation
Acq. announced
Quarterly results
Auditor change
Appointed director
CC transcript
Director departure

SEELOS THERAPEUTICS, INC. (APRI) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
06/29/2023 8-K Other Events  Interactive Data
05/19/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
Docs: "Certificate of Amendment to the Amended and Restated Articles of Incorporation of Seelos Therapeutics, Inc., filed May 18, 2023",
"Amendment No. 3 to Convertible Promissory Note, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management V, LLC",
"Form of Warrant",
"Form of Amendment No. 1 to Securities Purchase Agreement, by and between Seelos Therapeutics, Inc. and each purchaser identified on the signature pages thereto"
03/24/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Amended and Restated Bylaws of Seelos Therapeutics, Inc., effective as of March 23, 2023"
03/14/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "PRE-FUNDED COMMON STOCK PURCHASE WARRANT SEELOS THERAPEUTICS, INC. Warrant Shares: _______ Initial Exercise Date: March 14, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from Seelos Therapeutics, Inc., a Nevada corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .           &#8...",
"COMMON STOCK PURCHASE WARRANT SEELOS THERAPEUTICS, INC. Warrant Shares: _______ Initial Exercise Date: September 14, 2023 Issue Date: March 14, 2023 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September 14, 2023 and on or prior to 5:00 p.m. on September 14, 2028 but not thereafter, to subscribe for and purchase from Seelos Therapeutics, Inc., a Nevada corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .        &#823...",
"Brownstein Hyatt Farber Schreck, LLP",
"300 Park Avenue, 2nd Floor",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of March 10, 2023, between Seelos Therapeutics, Inc., a Nevada corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act , the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company and each Purchase..."
03/10/2023 8-K Investor presentation
Docs: "Corporate Presentation"
11/23/2022 8-K Quarterly results
09/01/2022 8-K Other Events  Interactive Data
05/23/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/22/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
04/11/2022 8-K Acquisition/merger/asset purchase announced
Docs: "Amendment No. 5 to Asset Purchase Agreement, by and between Seelos Corporation and Phoenixus AG",
"[email protected]"
01/10/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated Employment Agreement by and between Seelos Therapeutics, Inc. and Raj Mehra, Ph.D."
11/24/2021 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "EXCLUSIVE LICENSE AGREEMENT",
"COMMON STOCK PURCHASE AGREEMENT",
"Seelos Therapeutics Announces Acquisition of an Exclusive License of iX Biopharma’ s Proprietary Wafer-Based Delivery Platform for Sublingual Ketamine - New SLS-003 Program Extends Seelos’ Ketamine Franchise into Additional Indications Including Chronic Neuropathic Pain and Additional Psychiatric Disorders - Program has been Granted Orphan Drug Designation in the US for the Treatment of Complex Regional Pain Syndrome NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it has entered into an exclusive license agreement , whereby it acquired a worldwide license from iX Biopharma Ltd for Wafermine™, a sublingual racemi..."
11/24/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "FORM OF CONVERTIBLE PROMISSORY NOTE",
"SECURITIES PURCHASE AGREEMENT",
"Security Agreement, by and between Seelos Therapeutics, Inc. and Lind Global Asset Management V, LLC",
"PRESS RELASE"
10/25/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "SEELOS THERAPEUTICS ANNOUNCES SENIOR MANAGEMENT APPOINTMENTS"
09/02/2021 8-K Quarterly results
06/17/2021 8-K Quarterly results
05/24/2021 8-K Quarterly results
05/21/2021 8-K Quarterly results
05/20/2021 8-K Quarterly results
05/17/2021 8-K Quarterly results
02/18/2021 8-K Quarterly results
01/28/2021 8-K Other Events, Financial Statements and Exhibits
Docs: "Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares"
01/26/2021 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "UNDERWRITING AGREEMENT, DATED AS OF JANUARY 25, 2021",
"Opinion of Brownstein Hyatt Farber Schreck, LLP",
"Seelos Therapeutics Announces Pricing of $31.25 Million Public Offering of Common Stock"
01/11/2021 8-K Other Events
12/17/2020 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "FORM OF CONVERTIBLE PROMISSORY NOTE DUE DECEMBER 11, 2022.",
"SECURITIES PURCHASE AGREEMENT",
"SEELOS THERAPEUTICS, INC.,"
12/14/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
11/13/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
09/09/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "FORM OF WARRANT",
"OPINION",
"SECURITIES PURCHASE AGREEMENT, DATED SEPTEMBER 4, 2020",
"PLACEMENT AGENCY AGREEMENT, DATED SEPTEMBER 4, 2020",
"Seelos Therapeutics Announces Closing of $7.0 Million Registered Direct Offering"
06/11/2020 8-K Other Events
05/19/2020 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Amendment to the Amended and Restated Articles of Incorporation of Seelos Therapeutics, Inc., filed May 18, 2020"
05/15/2020 8-K Appointed a new director
Docs: "Seelos Therapeutics Announces Appointment of Judith Dunn to the Board of Directors NEW YORK, May 15, 2020"
04/24/2020 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy